Rezolute Reports Positive Phase 3 upLIFT Results, 13 of 16 Meet Response Criterion

Rezolute announced that its Phase 3 upLIFT study achieved its primary efficacy endpoint in preliminary results for ersodetug in tumor hyperinsulinism.Key Highlights:Original SEC Filing: Rezolute, Inc. [ RZLT ] - 8-K - Nov. 13, 2026This is an AI-powered summary. It may contain inaccuracies. Consider…